Leukemia-associated mutations in SHIP1 inhibit its enzymatic activity, interaction with the GM-CSF receptor and Grb2, and its ability to inactivate PI3K/AKT signaling

► SHIP1 mutations occur at a low frequency (3.1%) in acute myeloid leukemia patients. ► Identification of two new SHIP1 mutations i.e. T162P and R225W in 3 AML patients ► 4 out of 13 leukemia-associated SHIP1 mutants have lost a signaling function. ► The results further support a tumor suppressor function of SHIP1 in leukemogensis.